查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1872307

低分子量肝素原料药（API）－全球市场份额和排名、总收入和需求预测（2025-2031年）

Low Molecular Weight Heparin API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 116 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球低分子量肝素原料药市场规模估计为 7.3 亿美元，预计到 2031 年将成长至 13.91 亿美元，2025 年至 2031 年的复合年增长率为 8.0%。

本报告对近期关税调整和国际战略反制措施对低分子量肝素原料原料药跨境产业布局、资本配置模式、区域经济相互依存关係和供应链重组的影响进行了全面评估。

肝素是一种抗凝血剂（血液稀释药物），可防止血栓形成。它用于治疗和预防静脉、动脉或肺部血栓。它也用于术前以降低血栓风险。大多数肝素产品以肝素钠或肝素钙的形式存在。本报告主要关注低分子量肝素原料药（API）。

低分子量肝素（LMWH）原料药市场在全球製药业中扮演着举足轻重的角色，这主要归功于LMWH在预防和治疗血栓相关疾病（例如深层静脉栓塞症（DVT）和肺动脉栓塞（PE））方面的广泛应用。与未分级肝素相比，LMWH活性药物成分因其优异的药物动力学特性（例如，生物利用度高、半衰期长、副作用风险低）而优先用于临床应用。心血管疾病和静脉血栓栓塞症的日益普遍、人口老化以及全球外科手术数量的不断增长，都显着推动了对基于LMWH治疗方法的需求。

由于血栓相关疾病的高发生率和先进的医疗保健基础设施，北美和欧洲市场正在推动需求，而亚太地区由于医疗费用支出增加和学名药的兴起，正在成为一个成长型市场。

在低分子量肝素原料药领域，Enoxaparin Sodium占了相当大的份额，预计到 2030 年将达到 12.5882 亿美元，2024 年至 2030 年的复合年增长率为 12.46%。

全球低分子量肝素原料药的主要企业包括烟台东城药业、深圳海普林製药、南京金友生化药业、常州千虹生物製药、青岛九龙生物製药等。截至2023年，全球前五大生产商的收入份额将占全球总收入的约72.91%。

本报告旨在对全球低分子量肝素原料药市场按地区/国家、类型和应用进行全面分析，重点关注总销售量、收入、价格、市场份额和主要企业的排名。

低分子量肝素原料药市场规模、估算和预测以销售量（十亿）和收入（百万美元）为单位呈现，基准年为2024年，并包含2020年至2031年期间的历史数据和预测数据。定量和定性分析相结合，有助于读者制定业务和成长策略，评估市场竞争，分析自身在当前市场中的地位，并就低分子量肝素原料药做出明智的商业决策。

市场区隔

公司

  • Yantai Dongcheng Pharmaceutical
  • Shenzhen Hepalink Pharmaceutical
  • Nanjing King-friend
  • Changzhou Qianhong Biopharma
  • Qingdao Jiulong Biopharmaceutical
  • Dongying Tiandong Pharmaceutical
  • Yino Pharma
  • Opocrin
  • Hebei Changshan
  • Hubei Enoray Biopharmaceutical
  • Nanjing Nanda Pharmaceutical
  • Cisen Pharmaceutical

按类型分類的细分市场

  • 低分子量肝素钠
  • 低分子量肝素钙

应用领域

  • Enoxaparin Sodium
  • 那屈肝素钙
  • 达肝素钠
  • 亭札帕林钠
  • 帕那帕林钠

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Low Molecular Weight Heparin API was estimated to be worth US$ 730 million in 2024 and is forecast to a readjusted size of US$ 1391 million by 2031 with a CAGR of 8.0% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Low Molecular Weight Heparin API cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Heparin is an anticoagulant (blood thinner) that prevents the formation of blood clots. Heparin is used to treat and prevent blood clots in the veins, arteries, or lung. It is also used before surgery to reduce the risk of blood clots. Most of the Heparin product is existed in a form of Heparin Sodium or Heparin Calcium. In this report, we mainly study the low molecular weight heparin API.

The Low Molecular Weight Heparin (LMWH) API market plays a crucial role in the global pharmaceutical industry due to the widespread use of LMWHs in the prevention and treatment of blood clot-related disorders, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). LMWH APIs are preferred in clinical settings for their favorable pharmacological properties, including better bioavailability, longer half-life, and reduced risk of side effects compared to unfractionated heparin. The increasing prevalence of cardiovascular diseases and venous thromboembolism, aging populations, and a rise in surgical procedures worldwide have significantly driven demand for LMWH-based therapies.

The North American and European markets lead in demand due to a high prevalence of thrombosis-related conditions and advanced healthcare infrastructure. Asia-Pacific is emerging as a growth market, driven by increased healthcare spending and the rise of generics.

Low Molecular Weight Heparin API segment market, the Enoxaparin Sodium holds an important share, and it is expected to reach a value of US$ 1,258.82 million by 2030, at a CAGR of 12.46% during 2024 and 2030.

The global key companies of Low Molecular Weight Heparin API include Yantai Dongcheng Pharmaceutical, Shenzhen Hepalink Pharmaceutical, Nanjing King-friend Biochemical Pharmaceutical, Changzhou Qianhong Biopharma, and Qingdao Jiulong Biopharmaceutical, etc. In 2023, the global five largest players hold a share approximately 72.91% in terms of revenue.

This report aims to provide a comprehensive presentation of the global market for Low Molecular Weight Heparin API, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Low Molecular Weight Heparin API by region & country, by Type, and by Application.

The Low Molecular Weight Heparin API market size, estimations, and forecasts are provided in terms of sales volume (Billion Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Low Molecular Weight Heparin API.

Market Segmentation

By Company

  • Yantai Dongcheng Pharmaceutical
  • Shenzhen Hepalink Pharmaceutical
  • Nanjing King-friend
  • Changzhou Qianhong Biopharma
  • Qingdao Jiulong Biopharmaceutical
  • Dongying Tiandong Pharmaceutical
  • Yino Pharma
  • Opocrin
  • Hebei Changshan
  • Hubei Enoray Biopharmaceutical
  • Nanjing Nanda Pharmaceutical
  • Cisen Pharmaceutical

Segment by Type

  • Low Molecular Weight Heparin Sodium
  • Low Molecular Weight Heparin Calcium

Segment by Application

  • Enoxaparin Sodium
  • Nadroparin Calcium
  • Dalteparin Sodium
  • Tinzaparin Sodium
  • Parnaparin Sodium

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Low Molecular Weight Heparin API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Low Molecular Weight Heparin API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Low Molecular Weight Heparin API in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Low Molecular Weight Heparin API Product Introduction
  • 1.2 Global Low Molecular Weight Heparin API Market Size Forecast
    • 1.2.1 Global Low Molecular Weight Heparin API Sales Value (2020-2031)
    • 1.2.2 Global Low Molecular Weight Heparin API Sales Volume (2020-2031)
    • 1.2.3 Global Low Molecular Weight Heparin API Sales Price (2020-2031)
  • 1.3 Low Molecular Weight Heparin API Market Trends & Drivers
    • 1.3.1 Low Molecular Weight Heparin API Industry Trends
    • 1.3.2 Low Molecular Weight Heparin API Market Drivers & Opportunity
    • 1.3.3 Low Molecular Weight Heparin API Market Challenges
    • 1.3.4 Low Molecular Weight Heparin API Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Low Molecular Weight Heparin API Players Revenue Ranking (2024)
  • 2.2 Global Low Molecular Weight Heparin API Revenue by Company (2020-2025)
  • 2.3 Global Low Molecular Weight Heparin API Players Sales Volume Ranking (2024)
  • 2.4 Global Low Molecular Weight Heparin API Sales Volume by Company Players (2020-2025)
  • 2.5 Global Low Molecular Weight Heparin API Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Low Molecular Weight Heparin API Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Low Molecular Weight Heparin API Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Low Molecular Weight Heparin API
  • 2.9 Low Molecular Weight Heparin API Market Competitive Analysis
    • 2.9.1 Low Molecular Weight Heparin API Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Low Molecular Weight Heparin API Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Low Molecular Weight Heparin API as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Low Molecular Weight Heparin Sodium
    • 3.1.2 Low Molecular Weight Heparin Calcium
  • 3.2 Global Low Molecular Weight Heparin API Sales Value by Type
    • 3.2.1 Global Low Molecular Weight Heparin API Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Low Molecular Weight Heparin API Sales Value, by Type (2020-2031)
    • 3.2.3 Global Low Molecular Weight Heparin API Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Low Molecular Weight Heparin API Sales Volume by Type
    • 3.3.1 Global Low Molecular Weight Heparin API Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Low Molecular Weight Heparin API Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Low Molecular Weight Heparin API Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Low Molecular Weight Heparin API Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Enoxaparin Sodium
    • 4.1.2 Nadroparin Calcium
    • 4.1.3 Dalteparin Sodium
    • 4.1.4 Tinzaparin Sodium
    • 4.1.5 Parnaparin Sodium
  • 4.2 Global Low Molecular Weight Heparin API Sales Value by Application
    • 4.2.1 Global Low Molecular Weight Heparin API Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Low Molecular Weight Heparin API Sales Value, by Application (2020-2031)
    • 4.2.3 Global Low Molecular Weight Heparin API Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Low Molecular Weight Heparin API Sales Volume by Application
    • 4.3.1 Global Low Molecular Weight Heparin API Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Low Molecular Weight Heparin API Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Low Molecular Weight Heparin API Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Low Molecular Weight Heparin API Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Low Molecular Weight Heparin API Sales Value by Region
    • 5.1.1 Global Low Molecular Weight Heparin API Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Low Molecular Weight Heparin API Sales Value by Region (2020-2025)
    • 5.1.3 Global Low Molecular Weight Heparin API Sales Value by Region (2026-2031)
    • 5.1.4 Global Low Molecular Weight Heparin API Sales Value by Region (%), (2020-2031)
  • 5.2 Global Low Molecular Weight Heparin API Sales Volume by Region
    • 5.2.1 Global Low Molecular Weight Heparin API Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Low Molecular Weight Heparin API Sales Volume by Region (2020-2025)
    • 5.2.3 Global Low Molecular Weight Heparin API Sales Volume by Region (2026-2031)
    • 5.2.4 Global Low Molecular Weight Heparin API Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Low Molecular Weight Heparin API Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 5.4.2 North America Low Molecular Weight Heparin API Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 5.5.2 Europe Low Molecular Weight Heparin API Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Low Molecular Weight Heparin API Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 5.7.2 South America Low Molecular Weight Heparin API Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Low Molecular Weight Heparin API Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Low Molecular Weight Heparin API Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Low Molecular Weight Heparin API Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Low Molecular Weight Heparin API Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 6.3.2 United States Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Low Molecular Weight Heparin API Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 6.4.2 Europe Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Low Molecular Weight Heparin API Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 6.5.2 China Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Low Molecular Weight Heparin API Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 6.6.2 Japan Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Low Molecular Weight Heparin API Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 6.7.2 South Korea Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Low Molecular Weight Heparin API Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Low Molecular Weight Heparin API Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Low Molecular Weight Heparin API Sales Value, 2020-2031
    • 6.9.2 India Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Low Molecular Weight Heparin API Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Yantai Dongcheng Pharmaceutical
    • 7.1.1 Yantai Dongcheng Pharmaceutical Company Information
    • 7.1.2 Yantai Dongcheng Pharmaceutical Introduction and Business Overview
    • 7.1.3 Yantai Dongcheng Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Yantai Dongcheng Pharmaceutical Low Molecular Weight Heparin API Product Offerings
    • 7.1.5 Yantai Dongcheng Pharmaceutical Recent Development
  • 7.2 Shenzhen Hepalink Pharmaceutical
    • 7.2.1 Shenzhen Hepalink Pharmaceutical Company Information
    • 7.2.2 Shenzhen Hepalink Pharmaceutical Introduction and Business Overview
    • 7.2.3 Shenzhen Hepalink Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Shenzhen Hepalink Pharmaceutical Low Molecular Weight Heparin API Product Offerings
    • 7.2.5 Shenzhen Hepalink Pharmaceutical Recent Development
  • 7.3 Nanjing King-friend
    • 7.3.1 Nanjing King-friend Company Information
    • 7.3.2 Nanjing King-friend Introduction and Business Overview
    • 7.3.3 Nanjing King-friend Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Nanjing King-friend Low Molecular Weight Heparin API Product Offerings
    • 7.3.5 Nanjing King-friend Recent Development
  • 7.4 Changzhou Qianhong Biopharma
    • 7.4.1 Changzhou Qianhong Biopharma Company Information
    • 7.4.2 Changzhou Qianhong Biopharma Introduction and Business Overview
    • 7.4.3 Changzhou Qianhong Biopharma Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Changzhou Qianhong Biopharma Low Molecular Weight Heparin API Product Offerings
    • 7.4.5 Changzhou Qianhong Biopharma Recent Development
  • 7.5 Qingdao Jiulong Biopharmaceutical
    • 7.5.1 Qingdao Jiulong Biopharmaceutical Company Information
    • 7.5.2 Qingdao Jiulong Biopharmaceutical Introduction and Business Overview
    • 7.5.3 Qingdao Jiulong Biopharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Qingdao Jiulong Biopharmaceutical Low Molecular Weight Heparin API Product Offerings
    • 7.5.5 Qingdao Jiulong Biopharmaceutical Recent Development
  • 7.6 Dongying Tiandong Pharmaceutical
    • 7.6.1 Dongying Tiandong Pharmaceutical Company Information
    • 7.6.2 Dongying Tiandong Pharmaceutical Introduction and Business Overview
    • 7.6.3 Dongying Tiandong Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 Dongying Tiandong Pharmaceutical Low Molecular Weight Heparin API Product Offerings
    • 7.6.5 Dongying Tiandong Pharmaceutical Recent Development
  • 7.7 Yino Pharma
    • 7.7.1 Yino Pharma Company Information
    • 7.7.2 Yino Pharma Introduction and Business Overview
    • 7.7.3 Yino Pharma Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Yino Pharma Low Molecular Weight Heparin API Product Offerings
    • 7.7.5 Yino Pharma Recent Development
  • 7.8 Opocrin
    • 7.8.1 Opocrin Company Information
    • 7.8.2 Opocrin Introduction and Business Overview
    • 7.8.3 Opocrin Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Opocrin Low Molecular Weight Heparin API Product Offerings
    • 7.8.5 Opocrin Recent Development
  • 7.9 Hebei Changshan
    • 7.9.1 Hebei Changshan Company Information
    • 7.9.2 Hebei Changshan Introduction and Business Overview
    • 7.9.3 Hebei Changshan Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.9.4 Hebei Changshan Low Molecular Weight Heparin API Product Offerings
    • 7.9.5 Hebei Changshan Recent Development
  • 7.10 Hubei Enoray Biopharmaceutical
    • 7.10.1 Hubei Enoray Biopharmaceutical Company Information
    • 7.10.2 Hubei Enoray Biopharmaceutical Introduction and Business Overview
    • 7.10.3 Hubei Enoray Biopharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.10.4 Hubei Enoray Biopharmaceutical Low Molecular Weight Heparin API Product Offerings
    • 7.10.5 Hubei Enoray Biopharmaceutical Recent Development
  • 7.11 Nanjing Nanda Pharmaceutical
    • 7.11.1 Nanjing Nanda Pharmaceutical Company Information
    • 7.11.2 Nanjing Nanda Pharmaceutical Introduction and Business Overview
    • 7.11.3 Nanjing Nanda Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.11.4 Nanjing Nanda Pharmaceutical Low Molecular Weight Heparin API Product Offerings
    • 7.11.5 Nanjing Nanda Pharmaceutical Recent Development
  • 7.12 Cisen Pharmaceutical
    • 7.12.1 Cisen Pharmaceutical Company Information
    • 7.12.2 Cisen Pharmaceutical Introduction and Business Overview
    • 7.12.3 Cisen Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.12.4 Cisen Pharmaceutical Low Molecular Weight Heparin API Product Offerings
    • 7.12.5 Cisen Pharmaceutical Recent Development

8 Industry Chain Analysis

  • 8.1 Low Molecular Weight Heparin API Industrial Chain
  • 8.2 Low Molecular Weight Heparin API Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Low Molecular Weight Heparin API Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Low Molecular Weight Heparin API Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Low Molecular Weight Heparin API Market Trends
  • Table 2. Low Molecular Weight Heparin API Market Drivers & Opportunity
  • Table 3. Low Molecular Weight Heparin API Market Challenges
  • Table 4. Low Molecular Weight Heparin API Market Restraints
  • Table 5. Global Low Molecular Weight Heparin API Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Low Molecular Weight Heparin API Revenue Market Share by Company (2020-2025)
  • Table 7. Global Low Molecular Weight Heparin API Sales Volume by Company (2020-2025) & (Billion Units)
  • Table 8. Global Low Molecular Weight Heparin API Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Low Molecular Weight Heparin API Price by Company (2020-2025) & (US$/Billion Untis)
  • Table 10. Key Manufacturers Low Molecular Weight Heparin API Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Low Molecular Weight Heparin API Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Low Molecular Weight Heparin API
  • Table 13. Global Low Molecular Weight Heparin API Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Low Molecular Weight Heparin API as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Low Molecular Weight Heparin API Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Low Molecular Weight Heparin API Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Low Molecular Weight Heparin API Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Low Molecular Weight Heparin API Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Low Molecular Weight Heparin API Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Low Molecular Weight Heparin API Sales Volume by Type: 2020 VS 2024 VS 2031 (Billion Units)
  • Table 22. Global Low Molecular Weight Heparin API Sales Volume by Type (2020-2025) & (Billion Units)
  • Table 23. Global Low Molecular Weight Heparin API Sales Volume by Type (2026-2031) & (Billion Units)
  • Table 24. Global Low Molecular Weight Heparin API Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Low Molecular Weight Heparin API Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Low Molecular Weight Heparin API Price by Type (2020-2025) & (US$/Billion Untis)
  • Table 27. Global Low Molecular Weight Heparin API Price by Type (2026-2031) & (US$/Billion Untis)
  • Table 28. Global Low Molecular Weight Heparin API Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Low Molecular Weight Heparin API Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Low Molecular Weight Heparin API Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Low Molecular Weight Heparin API Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Low Molecular Weight Heparin API Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Low Molecular Weight Heparin API Sales Volume by Application: 2020 VS 2024 VS 2031 (Billion Units)
  • Table 34. Global Low Molecular Weight Heparin API Sales Volume by Application (2020-2025) & (Billion Units)
  • Table 35. Global Low Molecular Weight Heparin API Sales Volume by Application (2026-2031) & (Billion Units)
  • Table 36. Global Low Molecular Weight Heparin API Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Low Molecular Weight Heparin API Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Low Molecular Weight Heparin API Price by Application (2020-2025) & (US$/Billion Untis)
  • Table 39. Global Low Molecular Weight Heparin API Price by Application (2026-2031) & (US$/Billion Untis)
  • Table 40. Global Low Molecular Weight Heparin API Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Low Molecular Weight Heparin API Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Low Molecular Weight Heparin API Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Low Molecular Weight Heparin API Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Low Molecular Weight Heparin API Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Low Molecular Weight Heparin API Sales Volume by Region (Billion Units): 2020 VS 2024 VS 2031
  • Table 46. Global Low Molecular Weight Heparin API Sales Volume by Region (2020-2025) & (Billion Units)
  • Table 47. Global Low Molecular Weight Heparin API Sales Volume by Region (2026-2031) & (Billion Units)
  • Table 48. Global Low Molecular Weight Heparin API Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Low Molecular Weight Heparin API Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Low Molecular Weight Heparin API Average Price by Region (2020-2025) & (US$/Billion Untis)
  • Table 51. Global Low Molecular Weight Heparin API Average Price by Region (2026-2031) & (US$/Billion Untis)
  • Table 52. Key Countries/Regions Low Molecular Weight Heparin API Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Low Molecular Weight Heparin API Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Low Molecular Weight Heparin API Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Low Molecular Weight Heparin API Sales Volume, (2020-2025) & (Billion Units)
  • Table 56. Key Countries/Regions Low Molecular Weight Heparin API Sales Volume, (2026-2031) & (Billion Units)
  • Table 57. Yantai Dongcheng Pharmaceutical Company Information
  • Table 58. Yantai Dongcheng Pharmaceutical Introduction and Business Overview
  • Table 59. Yantai Dongcheng Pharmaceutical Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 60. Yantai Dongcheng Pharmaceutical Low Molecular Weight Heparin API Product Offerings
  • Table 61. Yantai Dongcheng Pharmaceutical Recent Development
  • Table 62. Shenzhen Hepalink Pharmaceutical Company Information
  • Table 63. Shenzhen Hepalink Pharmaceutical Introduction and Business Overview
  • Table 64. Shenzhen Hepalink Pharmaceutical Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 65. Shenzhen Hepalink Pharmaceutical Low Molecular Weight Heparin API Product Offerings
  • Table 66. Shenzhen Hepalink Pharmaceutical Recent Development
  • Table 67. Nanjing King-friend Company Information
  • Table 68. Nanjing King-friend Introduction and Business Overview
  • Table 69. Nanjing King-friend Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 70. Nanjing King-friend Low Molecular Weight Heparin API Product Offerings
  • Table 71. Nanjing King-friend Recent Development
  • Table 72. Changzhou Qianhong Biopharma Company Information
  • Table 73. Changzhou Qianhong Biopharma Introduction and Business Overview
  • Table 74. Changzhou Qianhong Biopharma Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 75. Changzhou Qianhong Biopharma Low Molecular Weight Heparin API Product Offerings
  • Table 76. Changzhou Qianhong Biopharma Recent Development
  • Table 77. Qingdao Jiulong Biopharmaceutical Company Information
  • Table 78. Qingdao Jiulong Biopharmaceutical Introduction and Business Overview
  • Table 79. Qingdao Jiulong Biopharmaceutical Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 80. Qingdao Jiulong Biopharmaceutical Low Molecular Weight Heparin API Product Offerings
  • Table 81. Qingdao Jiulong Biopharmaceutical Recent Development
  • Table 82. Dongying Tiandong Pharmaceutical Company Information
  • Table 83. Dongying Tiandong Pharmaceutical Introduction and Business Overview
  • Table 84. Dongying Tiandong Pharmaceutical Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 85. Dongying Tiandong Pharmaceutical Low Molecular Weight Heparin API Product Offerings
  • Table 86. Dongying Tiandong Pharmaceutical Recent Development
  • Table 87. Yino Pharma Company Information
  • Table 88. Yino Pharma Introduction and Business Overview
  • Table 89. Yino Pharma Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 90. Yino Pharma Low Molecular Weight Heparin API Product Offerings
  • Table 91. Yino Pharma Recent Development
  • Table 92. Opocrin Company Information
  • Table 93. Opocrin Introduction and Business Overview
  • Table 94. Opocrin Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 95. Opocrin Low Molecular Weight Heparin API Product Offerings
  • Table 96. Opocrin Recent Development
  • Table 97. Hebei Changshan Company Information
  • Table 98. Hebei Changshan Introduction and Business Overview
  • Table 99. Hebei Changshan Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 100. Hebei Changshan Low Molecular Weight Heparin API Product Offerings
  • Table 101. Hebei Changshan Recent Development
  • Table 102. Hubei Enoray Biopharmaceutical Company Information
  • Table 103. Hubei Enoray Biopharmaceutical Introduction and Business Overview
  • Table 104. Hubei Enoray Biopharmaceutical Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 105. Hubei Enoray Biopharmaceutical Low Molecular Weight Heparin API Product Offerings
  • Table 106. Hubei Enoray Biopharmaceutical Recent Development
  • Table 107. Nanjing Nanda Pharmaceutical Company Information
  • Table 108. Nanjing Nanda Pharmaceutical Introduction and Business Overview
  • Table 109. Nanjing Nanda Pharmaceutical Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 110. Nanjing Nanda Pharmaceutical Low Molecular Weight Heparin API Product Offerings
  • Table 111. Nanjing Nanda Pharmaceutical Recent Development
  • Table 112. Cisen Pharmaceutical Company Information
  • Table 113. Cisen Pharmaceutical Introduction and Business Overview
  • Table 114. Cisen Pharmaceutical Low Molecular Weight Heparin API Sales (Billion Units), Revenue (US$ Million), Price (US$/Billion Untis) and Gross Margin (2020-2025)
  • Table 115. Cisen Pharmaceutical Low Molecular Weight Heparin API Product Offerings
  • Table 116. Cisen Pharmaceutical Recent Development
  • Table 117. Key Raw Materials Lists
  • Table 118. Raw Materials Key Suppliers Lists
  • Table 119. Low Molecular Weight Heparin API Downstream Customers
  • Table 120. Low Molecular Weight Heparin API Distributors List
  • Table 121. Research Programs/Design for This Report
  • Table 122. Key Data Information from Secondary Sources
  • Table 123. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Low Molecular Weight Heparin API Product Picture
  • Figure 2. Global Low Molecular Weight Heparin API Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Low Molecular Weight Heparin API Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Low Molecular Weight Heparin API Sales Volume (2020-2031) & (Billion Units)
  • Figure 5. Global Low Molecular Weight Heparin API Sales Price (2020-2031) & (US$/Billion Untis)
  • Figure 6. Low Molecular Weight Heparin API Report Years Considered
  • Figure 7. Global Low Molecular Weight Heparin API Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Low Molecular Weight Heparin API Players Sales Volume Ranking (2024) & (Billion Units)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Low Molecular Weight Heparin API Revenue in 2024
  • Figure 10. Low Molecular Weight Heparin API Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. Low Molecular Weight Heparin Sodium Picture
  • Figure 12. Low Molecular Weight Heparin Calcium Picture
  • Figure 13. Global Low Molecular Weight Heparin API Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 14. Global Low Molecular Weight Heparin API Sales Value Market Share by Type, 2024 & 2031
  • Figure 15. Global Low Molecular Weight Heparin API Sales Volume by Type (2020 VS 2024 VS 2031) & (Billion Units)
  • Figure 16. Global Low Molecular Weight Heparin API Sales Volume Market Share by Type, 2024 & 2031
  • Figure 17. Global Low Molecular Weight Heparin API Price by Type (2020-2031) & (US$/Billion Untis)
  • Figure 18. Product Picture of Enoxaparin Sodium
  • Figure 19. Product Picture of Nadroparin Calcium
  • Figure 20. Product Picture of Dalteparin Sodium
  • Figure 21. Product Picture of Tinzaparin Sodium
  • Figure 22. Product Picture of Parnaparin Sodium
  • Figure 23. Global Low Molecular Weight Heparin API Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 24. Global Low Molecular Weight Heparin API Sales Value Market Share by Application, 2024 & 2031
  • Figure 25. Global Low Molecular Weight Heparin API Sales Volume by Application (2020 VS 2024 VS 2031) & (Billion Units)
  • Figure 26. Global Low Molecular Weight Heparin API Sales Volume Market Share by Application, 2024 & 2031
  • Figure 27. Global Low Molecular Weight Heparin API Price by Application (2020-2031) & (US$/Billion Untis)
  • Figure 28. North America Low Molecular Weight Heparin API Sales Value (2020-2031) & (US$ Million)
  • Figure 29. North America Low Molecular Weight Heparin API Sales Value by Country (%), 2024 VS 2031
  • Figure 30. Europe Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. Europe Low Molecular Weight Heparin API Sales Value by Country (%), 2024 VS 2031
  • Figure 32. Asia Pacific Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. Asia Pacific Low Molecular Weight Heparin API Sales Value by Region (%), 2024 VS 2031
  • Figure 34. South America Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. South America Low Molecular Weight Heparin API Sales Value by Country (%), 2024 VS 2031
  • Figure 36. Middle East & Africa Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. Middle East & Africa Low Molecular Weight Heparin API Sales Value by Country (%), 2024 VS 2031
  • Figure 38. Key Countries/Regions Low Molecular Weight Heparin API Sales Value (%), (2020-2031)
  • Figure 39. Key Countries/Regions Low Molecular Weight Heparin API Sales Volume (%), (2020-2031)
  • Figure 40. United States Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. United States Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
  • Figure 42. United States Low Molecular Weight Heparin API Sales Value by Application (%), 2024 VS 2031
  • Figure 43. Europe Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. Europe Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
  • Figure 45. Europe Low Molecular Weight Heparin API Sales Value by Application (%), 2024 VS 2031
  • Figure 46. China Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. China Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
  • Figure 48. China Low Molecular Weight Heparin API Sales Value by Application (%), 2024 VS 2031
  • Figure 49. Japan Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 50. Japan Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
  • Figure 51. Japan Low Molecular Weight Heparin API Sales Value by Application (%), 2024 VS 2031
  • Figure 52. South Korea Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 53. South Korea Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
  • Figure 54. South Korea Low Molecular Weight Heparin API Sales Value by Application (%), 2024 VS 2031
  • Figure 55. Southeast Asia Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 56. Southeast Asia Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
  • Figure 57. Southeast Asia Low Molecular Weight Heparin API Sales Value by Application (%), 2024 VS 2031
  • Figure 58. India Low Molecular Weight Heparin API Sales Value, (2020-2031) & (US$ Million)
  • Figure 59. India Low Molecular Weight Heparin API Sales Value by Type (%), 2024 VS 2031
  • Figure 60. India Low Molecular Weight Heparin API Sales Value by Application (%), 2024 VS 2031
  • Figure 61. Low Molecular Weight Heparin API Industrial Chain
  • Figure 62. Low Molecular Weight Heparin API Manufacturing Cost Structure
  • Figure 63. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 64. Bottom-up and Top-down Approaches for This Report
  • Figure 65. Data Triangulation
  • Figure 66. Key Executives Interviewed